Chuka's questions to Kyverna Therapeutics Inc (KYTX) leadership • Q3 2024
Question
Speaking for Andy Chen, Chuka asked for clarification on the IRAK4 trial changes, questioning if Sanofi's addition of a dose was related to any safety or efficacy signals from previous doses.
Answer
Founder, President, and CEO Nellie Monofi clarified that the addition of a dose group is not due to any concerns about safety or efficacy. Instead, it is a strategic move to fulfill regulatory dose-ranging requirements, which will accelerate the program's path to Phase 3 registration studies upon completion of the current trials.